NYSEAMERICAN:OSTX OS Therapies Q2 2026 Earnings Report $1.64 -0.01 (-0.85%) As of 09:41 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast OS Therapies EPS ResultsActual EPS-$0.20Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOS Therapies Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOS Therapies Announcement DetailsQuarterQ2 2026Date8/14/2026TimeAfter Market ClosesConference Call DateFriday, August 14, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) OS Therapies Earnings HeadlinesAnalysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Axalta Coating Systems (AXTA)September 22 at 1:18 PM | theglobeandmail.comQ3 EPS Estimates for OS Therapies Boosted by AnalystSeptember 13, 2026 | americanbankingnews.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 24 at 1:00 AM | Paradigm Press (Ad)OS Therapies Announces Prospectus for Secondary Share ResalesSeptember 10, 2026 | tipranks.comOS Therapies Stockholders Approve Incentive Plan and BoardSeptember 9, 2026 | tipranks.comOS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma ...September 8, 2026 | finance.yahoo.comSee More OS Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OS Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OS Therapies and other key companies, straight to your email. Email Address About OS TherapiesOS Therapies (NYSEAMERICAN:OSTX), Inc. is a clinical-stage biotechnology company focused on developing treatments for osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults, as well as other solid tumors. The company’s work is aimed at addressing significant unmet medical needs in cancers for which treatment options remain limited. Its lead investigational product, OST-HER2, is an immunotherapy designed to target tumors that express the HER2 protein. OS Therapies has been evaluating OST-HER2 in clinical studies involving patients with recurrent or metastatic osteosarcoma. The company’s development strategy centers on advancing targeted therapies through clinical testing and potential regulatory approval. OS Therapies conducts its research and clinical development activities in collaboration with medical institutions and investigators. The company is headquartered in the United States and serves the oncology market through the development of therapies intended for patients with rare and difficult-to-treat cancers.View OS Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
